瑞典隆德大學(xué)（Lund University）的一個研究小組最新的研究發(fā)現(xiàn),，對于正在接受他莫昔芬 （Tamoxifen）藥物治療的乳腺癌患者,，每天多喝幾杯散發(fā)濃濃香氣的熱咖啡，能夠降低愈后乳腺癌復(fù)發(fā)的風(fēng)險,。
多年來（平均時間5年）,，該研究小組追蹤了來自瑞典南部的600多名乳腺癌患者，其中大約300名患者接受他莫昔芬藥物治療,。他莫昔芬是乳腺癌手術(shù)切除后降低癌癥復(fù)發(fā)的常用藥物,。研究人員比較了每天喝一杯或更少咖啡，以及每天喝兩杯或更多咖啡的乳腺癌患者,，結(jié)果表明多喝咖啡的患者他們的乳腺癌復(fù)發(fā)幾率要比喝咖啡少的患者降低一半還要多,。 然而，雖然該研究表明咖啡對乳腺癌治療的益處,，但咖啡是如何發(fā)揮作用的,，研究人員對此依然不得而知。不過研究人員猜測可能是由于咖啡進一步"激發(fā)"了他莫昔芬的藥性,，使得它治療效果更強,。
另外，隆德大學(xué)的研究人員早就發(fā)現(xiàn)喝咖啡與降低女性患乳腺癌的幾率之間的關(guān)聯(lián),。大量研究也表明咖啡中的有效成分－咖啡因－對癌細胞的生長有抑制作用,。這一系列的研究結(jié)果，一定會讓整天忙忙碌碌身心疲憊的都市女白領(lǐng)們歡心雀躍吧：咖啡,，不但讓我一整天精神抖擻,，而且給我?guī)砩眢w健康！（生物谷Bioon.com）
DOI: 10.1007/s10552-013-0169-1
Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status
Maria Simonsson, Viktoria Söderlind, Maria Henningson, Maria Hjertberg, Carsten Rose, Christian Ingvar, Helena Jernström
Purpose
Whether coffee modulates response to endocrine therapy in breast cancer patients is currently unknown. The CYP1A2 and CYP2C8 enzymes contribute to tamoxifen and caffeine metabolism. The purpose was to investigate the impact of coffee consumption on tumor characteristics and risk for early events in relation to breast cancer treatment and CYP1A2 and CYP2C8 genotypes.
Methods
Questionnaires regarding lifestyle were completed preoperatively by 634 patients in southern Sweden. CYP1A2*1F and CYP2C8*3 were genotyped. Clinical data and tumor characteristics were obtained from patients’ charts, population registries, and pathology reports. Coffee consumption was categorized as low (0–1 cups/day), moderate (2–4 cups/day), or high (5+ cups/day).
Results
The proportion of estrogen receptor negative (ER–) tumors increased with increasing coffee consumption (p trend = 0.042). Moderate to high consumption was associated with lower frequency of discordant receptor status (ER + PgR–) OR 0.38 (0.23–0.63) compared to low consumption. Median follow-up time was 4.92 (IQR 3.01–6.42) years. Tamoxifen-treated patients with ER+ tumors (n = 310) who consumed two or more cups/day had significantly decreased risk for early events compared to patients with low consumption, adjusted HR 0.40 (0.19–0.83). Low consumption combined with at least one CYP1A2*1F C-allele (n = 35) or CYP2C8*3 (n = 13) was associated with a high risk for early events in tamoxifen-treated patients compared to other tamoxifen-treated patients, adjusted HRs 3.49 (1.54–7.91) and 6.15 (2.46–15.36), respectively.
Conclusion
Moderate to high coffee consumption was associated with significantly decreased risk for early events in tamoxifen-treated patients and modified hormone receptor status. If confirmed, new recommendations regarding coffee consumption during tamoxifen treatment may be warranted.
